Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, presented collaborative data at the Cancer Advance Conference at Harvard Medical School from proof-of-principle imaging studies using tilmanocept-Cy3, a fluorescent-labeled agent from the Company’s Manocept™ platform, utilizing technical principle underlying Navidea’s FDA-approved lymphatic mapping product, Lymphoseek ® (technetium 99m tilmanocept) Injection. Data presented at the conference establish the feasibility of using Manocept compounds to bind to the CD206 mannose receptor and target macrophage inflammatory cells, an approach that may enable the design of novel immune cell-targeted agents for diagnosis and disease staging.
These studies using human tissue, animal model and in vitro analyses focused on establishing the ability of fluorescent tilmanocept-Cy3 to target macrophages in two disease states which are representative of broader macrophage-associated disorders: Kaposi’s Sarcoma (KS) and Tuberculosis (TB), both outside the current lymphatic mapping application. These data support the expansion of the Manocept platform into potential new indications in macrophage-mediated disorders, utilizing immune-cell targeting to address unmet diagnostic needs in this emerging area. Other recognized macrophage-mediated disorders include not only KS and TB, but rheumatoid arthritis, Systemic Lupus Erythematosis, atherosclerosis/vulnerable plaque, Crohn’s disease and others that span clinical areas in oncology, autoimmunity, infectious diseases, cardiology, and inflammation.
“Today’s conference emphasized the medical need for innovative precision diagnostics in the pursuit of better patient outcomes in a range of diseases,” commented Dr. Mark Pykett, Navidea CEO. “With the US approval and commercialization of our Lymphoseek product using CD206-targeting technology, we believe now is an opportune time to unveil the extension of our platform to promising new areas. These newly developed data suggest that our Manocept platform represents an opportunity to exploit the CD206-targeting mechanism underlying Lymphoseek and focus on new areas of diagnostic need beyond lymphatic mapping. We are encouraged by these data, provided by key experts in the field, supporting this principle. We intend to continue to evaluate emerging data in other disease states to define areas of focus, development pathways and partnering options to capitalize on this innovative platform," added Dr. Pykett.